EGFR TKIs can reversibly and selectively inhibit the activity and phosphorylation of EGFR-related tyrosine kinases by competitively binding to ATP sites on the structural domains of the intracellular tyrosine kinases, thus inhibiting EGFR downstream signaling, accelerating apoptosis, antagonizing angiogenesis, inhibiting tumor metastasis, and blocking tumor growth (7, 8). Here, EGFR is linked to neoplasm.